pentoxifylline + rifaximin

Pentoxifylline + rifaximin is a combination of two small molecule drugs used experimentally for the treatment of liver-related complications, particularly in patients with hepatopulmonary syndrome and alcoholic hepatitis. Pentoxifylline is a methylxanthine derivative that acts as a non-selective phosphodiesterase inhibitor, improving microcirculation and reducing inflammation by inhibiting tumor necrosis factor-alpha (TNF-α) synthesis. Rifaximin is a non-absorbable antibiotic that modulates gut microbiota, reduces ammonia-producing bacteria, and lowers systemic endotoxin levels. The combination has been studied in clinical trials for its potential to improve outcomes in patients who are refractory to pentoxifylline alone[1][2][3][7].